The Polymyositis Pipeline Is Booming With the Influx of the Key Companies Along With the Anticipated Novel Drugs

Polymyositis Pipeline
DelveInsight’s Polymyositis pipeline report covers the emerging drugs profiles, including clinical and nonclinical products.

DelveInsight’s Polymyositis pipeline report covers the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Key Takeaways from the Polymyositis Pipeline Report

The Polymyositis pipeline consists of therapies in different clinical phase stages, including KZR-616, PN-101, PF1801, VIB7734, and others. 
Leading players actively working to improve the Polymyositis treatment landscape are Kezar Life Sciences, Inc, Paean Biotechnology, ImmunoForge, Viela Bio, Cytodyn, and others.
The US Food and Drug Administration granted Orphan Drug Designations (ODD) for KZR-616 in October 2020 to treat polymyositis and dermatomyositis.
Polymyositis therapies in the late stage of development include KZR-616 (Kezar Life Sciences) and others.
PF1801 is being developed and investigated in the early stage of development by Viela Bio.

Get a detailed analysis of the pipeline landscape @ Polymyositis Pipeline Analysis

Polymyositis Overview

Polymyositis is a type of inflammatory myopathy, a group of muscle diseases marked by chronic muscle inflammation and weakness. Polymyositis (PM) is an autoimmune disorder that develops as a result of abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens and extramural solid muscular expression of major histocompatibility complex 1, which causes damage to the endomysium of skeletal muscles. Polymyositis develops gradually and rarely affects people under the age of 18.

Polymyositis Symptoms 

The following are the most common Polymyositis signs and symptoms:

Weakness in the muscles closest to the body’s center, such as the forearms, thighs, hips, shoulders, neck, and back
Weakness in the fingers and toes can occur at times.
Falling and having difficulty getting up after a fall
Dry cough that persists
Swallowing Difficulties (dysphagia)

Polymyositis Treatment

Polymyositis is managed using a combination of pharmacological and non-pharmacological treatments. Corticosteroids are the most commonly used pharmacological treatment. Prednisone and methylprednisolone are the most widely used corticosteroids for polymyositis, with a starting dose of 1mg/kg of prednisone per day.

Polymyositis Pipeline Analysis: Drug Profiles

KZR-616: Kezar Life Sciences

Product Description

KZR-616 is a first-in-class selective immunoproteasome inhibitor with broad therapeutic potential in various autoimmune diseases. Through selective immunoproteasome inhibition, KZR-616 provides a novel approach to immune system harmonization.

Phase II

NCT04033926: In January 2020, Kezar Life Sciences launched a Phase II randomized, double-blind, placebo-controlled, multicenter study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and Pharmacodynamics (PD) of KZR-616 treatment in patients with active Polymyositis or Dermatomyositis. During the Screening Period, patients will be evaluated for eligibility.

Polymyositis Pipeline Therapies and Key Companies

KZR-616: Kezar Life Sciences, Inc
PN-101: Paean Biotechnology
PF1801: ImmunoForge
VIB7734: Viela Bio

Find out the emerging therapies and companies @ Polymyositis Clinical Trials

Polymyositis Therapeutics Assessment

By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory

Scope of the Report

Coverage: Global

Polymyositis Key Players: Kezar Life Sciences, Inc, Paean Biotechnology, ImmunoForge, Viela Bio, Cytodyn, among others

Polymyositis Pipeline Therapies: KZR-616, PN-101, PF1801, VIB7734, and others

Table of Contents 

1.

Introduction

2.

Executive Summary

3.

Polymyositis: Overview

4.

Pipeline Therapeutics

5.

Late Stage Products (Phase III)

6.

Late Stage Products (Phase  III)

7.

Mid Stage Products (Phase  II)

8.

Early Stage Products (Phase I)

9.

Early Stage Products (Phase I)

10.

Preclinical Stage Products

11.

Therapeutic Assessment

12.

Inactive Products

13.

Collaborations Assessment- Licensing / Partnering / Funding

14.

Polymyositis- Unmet Needs

15.

Polymyositis- Market Drivers and Barriers

16.

Appendix

17.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Key questions answered in the Polymyositis Pipeline Report

What are the Polymyositis treatments available?
How many pharmaceutical companies are working on Polymyositis treatments?
Which of these firms’ pharmaceuticals is the most widely used?
How many Polymyositis medications is each company producing?
How many are drugs aimed at Polymyositis in the early, middle, or late stages of development?
How many of the current therapies can be used alone or in combination with other treatments?
What are the most important Polymyositis collaborations, mergers and acquisitions, and licensing practices?

Related Reports

Polymyositis Market

DelveInsight’s “Polymyositis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology, and the Polymyositis market trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/